Skip to main content

Table 1 Baseline characteristics

From: Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment

Variable OSI (n = 60) AFA (n = 64) p value
Age (years) 64.24 ± 12.33 64.13 ± 13.72 0.72a
Sex (male/female), No.% 25/35 28/36 0.82b
BMI (kg/m2) 23.74 ± 2.31 24.15 ± 2.46 0.26a
Smoking status, No.%    0.81c
 Never a smoker 11 13  
 Former smokers 32 30  
 Current smokers 17 21  
Time from diagnosis of NSCLC (months), No.%    0.78c
 < 6 15 17  
 6–12 35 33  
 > 12 10 14  
Largest size of brain metastasis, No.%    0.31c
 ≤ 10 mm 22 18  
 > 10 mm 38 46  
Number of brain metastases, No.%    0.47c
 ≤ 3 32 30  
 > 3 28 34  
Previous EGFR-TKI therapy, No.%    0.41c
 Erlotinib 23 20  
 Gefitinib 16 18  
 Afatinib 21 26  
Type of EGFR mutation, No.%    0.91c
 T790M and Exon 19 deletion 35 38  
 T790M and Exon 21 L858R 25 26  
Distant metastasis except for CNS, No.%    0.54c
 Gastrointestinal 22 18  
 Pancreas 11 14  
 Liver 12 16  
 Pancreas 12 14  
 Other 3 2  
ECOG performance status, No.%    0.97c
 0 9 12  
 1 27 25  
 2 24 27  
  1. OSI osimertinib, AFA afatinib, BMI body mass index, NSCLC non-small-cell lung cancer, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor, CNS central nervous system, ECOG Eastern Cooperative Oncology Group
  2. aAnalysed using independent-samples t-test
  3. bAnalysed using Chi-squared test
  4. cAnalysed using the Mann–Whitney test